BVF Partners LP has recently announced that it has increased stake in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 110.20%. After grabbing 7.06 million shares, the institutional investor is now in possession of 3.7 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 9.97% having worth around $6.18 million. Moreover, BlackRock Fund Advisors increased its share by 42707.0 to have a control over 4.87 million shares. And Tang Capital Management LLC raised its holdings to 4.34 million shares by acquiring 4.34 million shares or 6.12% of the stake.
Aclaris Therapeutics Inc (ACRS) concluded trading on December 20, 2023 at a closing price of $0.94, with 6.13 million shares of worth about $5.77 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -90.86% during that period and On Wednesday the price saw a loss of about -8.33%. Currently the company’s common shares owned by public are about 66.69M shares, out of which, 58.59M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 51 times over the past 12 months. They bought 364,672 shares in 29 of the transactions. In 22 selling transactions, insiders dumped 199,367 shares.
iShares Russell 2000 ETF, Vanguard Total Stock Market ETF, and Xtrackers SICAV – S&P 500 Swap UC are the top 3 mutual funds which are holding stakes in Aclaris Therapeutics Inc iShares Russell 2000 ETF is currently holding 1.89 million shares of worth totaling $1.65 million. The company recently came buying 930.0 shares which brought its stake up to 2.67% of the company’s outstanding shares. Xtrackers SICAV – S&P 500 Swap UC, after buying 0.92 million shares, have now control over 1.30% of the stake in the company. It holds 0.0 shares of worth $0.81 million.
However, the stock later moved at a day high price of 0.9999, or with a loss of -8.33%. Stock saw a price change of -14.22% in past 5 days and over the past one month there was a price change of -0.55%. Year-to-date (YTD), ACRS shares are showing a performance of -94.06% which decreased to -93.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.59 but also hit the highest price of $18.54 during that period. The average intraday trading volume for Aclaris Therapeutics Inc shares is 4.31 million. The stock is currently trading -1.89% below its 20-day simple moving average (SMA20), while that difference is down -68.51% for SMA50 and it goes to -86.98% lower than SMA200.
BVF Partners LP acquired 7.06 million shares of Aclaris Therapeutics Inc having value of about $6.18 million. Data submitted at the U.S SEC by BVF Partners LP revealed that the firm now holds 3.7 million shares in the company valued at close to $3481567.3, or have control over 110.20% stake in the company. Aclaris Therapeutics Inc (NASDAQ: ACRS) currently have 66.69M outstanding shares and institutions hold larger chunk of about 82.95% of that. Holding of mutual funds in the company is about 36.16% while other institutional holders and individual stake holders have control over 61.09% and 21.89% of the stake respectively.
The stock has a current market capitalization of $66.24M and its 3Y-monthly beta is at 0.17. It has posted earnings per share of -$1.67 in the same period. It has Quick Ratio of 4.50 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ACRS, volatility over the week remained 12.75% while standing at 11.30% over the month.
Analysts are in expectations that Aclaris Therapeutics Inc (ACRS) stock would likely to be making an EPS of -$0.38 in the current quarter, while forecast for next quarter EPS is -$0.34 and it is -$1.33 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.5 which is -$0.18 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.41 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -23.45% while it is estimated to increase by 18.80% in next year.
